# Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant

> **NIH NIH P50** · DANA-FARBER CANCER INST · 2021 · $2,264,107

## Abstract

Project Summary (Overall)
 The Overall section of this Ovarian Cancer SPORE application describes the Background,
Specific Aims, Innovation, and Research Plan of the three projects and four cores. We emphasize intra-
SPORE collaborations and development of clinical trials with companion biomarkers. Through this SPORE
application, we have tried to address several of the most urgent questions in ovarian cancer therapy. First,
PARP inhibitors are a new and essential feature of high grade serous ovarian cancer (HGSC) therapy, but
many patients eventually have cancer progression on these agents. Accordingly, in Project 1, we have
designed clinical trials with drug combinations and correlative studies which will allow us to systematically
extend the use of PARP inhibitors. Second, we recognize the emerging impact of immunotherapy on solid
tumor treatment. Thus, in Project 2, we have designed a novel vaccine trial for ovarian cancer patients. Third,
HGSC patients with primary refractory disease or those patients with recurrence whose cancer harbor
underlying RAS mutations such as low grade serous or mucinous cancers pose a particularly difficult clinical
problem. Accordingly, in Project 3, we will explore novel non-platinum drug combinations, such as the
combination of a BCL inhibitor and a MEK inhibitor, and will examine predictive biomarkers and tumor
responses evident in the extracellular activity. The Specific Aims of this DF/HCC ovarian cancer SPORE are as
follows: Aim 1 (Project 1): ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous
ovarian cancer (HGSOC); Aim 2 (Project 2): Combined personal neoantigen-targeting cancer vaccines with
immune checkpoint blockade for ovarian cancer; Aim 3 (Project 3): Evaluation of the Efficacy of Trametinib +
Navitoclax in recurrent ovarian carcinoma.

## Key facts

- **NIH application ID:** 10228046
- **Project number:** 5P50CA240243-02
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** ALAN D. D'ANDREA
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,264,107
- **Award type:** 5
- **Project period:** 2020-08-03 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10228046

## Citation

> US National Institutes of Health, RePORTER application 10228046, Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant (5P50CA240243-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10228046. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*